Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Caregiver MTS treatment satisfaction at endpoint, ITT population

From: Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?

MSS Summary

Agreement, %a

N = 161

Satisfied with frequency of daily dosing

97.5

Satisfied with ease of use

96.2

Child rarely missing a dose

97.5

Satisfied with child's behavior

93.8

Improvement in child's social interactions

82.6

Satisfied with how child pays attention

91.9

Satisfied with duration of effect on symptoms

93.1

Overall satisfaction

93.8

  1. a"Strongly agree", "agree", and "somewhat agree" were combined into the "agreed" category.
  2. MTS = methylphenidate transdermal system; ITT = intent to treat, MSS = Medication Satisfaction Survey.
Back to article page

Child and Adolescent Psychiatry and Mental Health

ISSN: 1753-2000